Vis enkel innførsel

dc.contributor.authorSnipstad, Sofie
dc.contributor.authorSulheim, Einar
dc.contributor.authorDavies, Catharina de Lange
dc.contributor.authorMoonen, Chrit
dc.contributor.authorStorm, Gert
dc.contributor.authorKiessling, Fabian
dc.contributor.authorSchmid, Ruth
dc.contributor.authorLammers, Twan
dc.date.accessioned2020-12-21T07:29:22Z
dc.date.available2020-12-21T07:29:22Z
dc.date.created2019-01-02T13:59:58Z
dc.date.issued2018
dc.identifier.citationExpert Opinion on Drug Delivery. 2018, 15 (12), 1249-1261.en_US
dc.identifier.issn1742-5247
dc.identifier.urihttps://hdl.handle.net/11250/2720443
dc.description.abstractIntroduction: Ultrasound in combination with microbubbles can make cells and tissues more accessible for drugs, thereby achieving improved therapeutic outcomes. In this review, we introduce the term ‘sonopermeation’, covering mechanisms such as pore formation (traditional sonoporation), as well as the opening of intercellular junctions, stimulated endocytosis/transcytosis, improved blood vessel perfusion and changes in the (tumor) microenvironment. Sonopermeation has gained a lot of interest in recent years, especially for delivering drugs through the otherwise impermeable blood-brain barrier, but also to tumors. Areas covered: In this review, we summarize various in vitro assays and in vivo setups that have been employed to unravel the fundamental mechanisms involved in ultrasound-enhanced drug delivery, as well as clinical trials that are ongoing in patients with brain, pancreatic, liver and breast cancer. We summarize the basic principles of sonopermeation, describe recent findings obtained in (pre-) clinical trials, and discuss future directions. Expert Opinion: We suggest that an improved mechanistic understanding, and microbubbles and ultrasound equipment specialized for drug delivery (and not for imaging) are key aspects to create more effective treatment regimens by sonopermeation. Real-time feedback and tools to predict therapeutic outcome and which tumors/patients will benefit from sonopermeation-based interventions will be important to promote clinical translation.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.urihttps://www.tandfonline.com/doi/full/10.1080/17425247.2018.1547279
dc.subjectblood-brain barrieren_US
dc.subjectcanceren_US
dc.subjectmicrobubbleen_US
dc.subjectultrasounden_US
dc.subjectsonoporationen_US
dc.subjectSonopermeationen_US
dc.titleSonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.rights.holderThis is an accepted manuscript of an article published by Taylor & Francis in Expert Opinion on Drug Delivery on 19 Nov 2018, available at https://doi.org/10.1080/17425247.2018.1547279en_US
dc.source.pagenumber1249-1261en_US
dc.source.volume15en_US
dc.source.journalExpert Opinion on Drug Deliveryen_US
dc.source.issue12en_US
dc.identifier.doi10.1080/17425247.2018.1547279
dc.identifier.cristin1648689
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU:en_US
cristin.unitcode7401,80,1,0
cristin.unitnameBioteknologi og nanomedisin
cristin.ispublishedtrue
cristin.fulltextpreprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel